Emicizumab Prophylaxis Administered Once-weekly or Every Two Weeks Provides Effective Bleed Prevention in Persons with Hemophilia A (PwHA) without Inhibitors - Results from the Phase III HAVEN 3 Study
2019
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI